BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug** Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading
** Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause
** Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co
** Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy
** Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL
** As of last close, stock up ~17% over the past year
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments